All of the shares are being offered by the company. The underwriters have an option to buy up to 3,543,763 more shares, for up to 30 days.
The offering is made under a shelf registration statement declared effective by the
Among its products under development, the company is making cellular immunotherapies for cancer. It has developed versions of the breakthrough CAR T cell immunotherapy and other cell-based cancer therapies.
But while that approach currently requires genetic engineering of cells taken from the patient,
Last June, the company announced a cancer immunotherapy deal with Chinese drug maker
The company's most clinically advanced drugs are four monoclonal antibodies that have completed Phase 3 trials in
(c)2017 The San Diego Union-Tribune
Visit The San Diego Union-Tribune at www.sandiegouniontribune.com
Distributed by Tribune Content Agency, LLC.